Ono Pharmaceutical Co. Ltd

Company Profile

Ono Pharmaceutical Co. Ltd had its IPO on under the ticker symbol OPHLF.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Ono Pharmaceutical Co. Ltd has a staff strength of 3,761 employees.

Stock update

Shares of Ono Pharmaceutical Co. Ltd opened at $19.83 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $19.83 - $19.83, and closed at $19.83.

This is a 0% increase from the previous day's closing price.

A total volume of 27 shares were traded at the close of the day’s session.

In the last one week, shares of Ono Pharmaceutical Co. Ltd have increased by +11.53%.

Ono Pharmaceutical Co. Ltd's Key Ratios

Ono Pharmaceutical Co. Ltd has a market cap of $9.68 billion, indicating a price to book ratio of 2.2859 and a price to sales ratio of 0.0308.

In the last 12-months Ono Pharmaceutical Co. Ltd’s revenue was $460.48 billion with a gross profit of $267.85 billion and an EBITDA of $170.91 billion. The EBITDA ratio measures Ono Pharmaceutical Co. Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ono Pharmaceutical Co. Ltd’s operating margin was 33.28% while its return on assets stood at 11.71% with a return of equity of 15.93%.

In Q2, Ono Pharmaceutical Co. Ltd’s quarterly earnings growth was a positive 7.9% while revenue growth was a positive 12.5%.

Ono Pharmaceutical Co. Ltd’s PE and PEG Ratio

Forward PE

11.5473

Trailing PE

12.4717

PEG

40586.9

Its diluted EPS in the last 12-months stands at $1.59 per share while it has a forward price to earnings multiple of 11.5473 and a PEG multiple of 40586.9. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ono Pharmaceutical Co. Ltd’s profitability.

Ono Pharmaceutical Co. Ltd stock is trading at a EV to sales ratio of 0.0276 and a EV to EBITDA ratio of 0.0765. Its price to sales ratio in the trailing 12-months stood at 0.0308.

Ono Pharmaceutical Co. Ltd stock pays annual dividends of $70 per share, indicating a yield of 2.99% and a payout ratio of 29.83%.

Balance sheet and cash flow metrics

Total Assets

$871.88 billion

Total Liabilities

$91.51 billion

Operating Cash Flow

$0

Capital Expenditure

$7.74 billion

Dividend Payout Ratio

29.83%

Ono Pharmaceutical Co. Ltd ended 2024 with $871.88 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $871.88 billion while shareholder equity stood at $762.49 billion.

Ono Pharmaceutical Co. Ltd ended 2024 with $0 in deferred long-term liabilities, $91.51 billion in other current liabilities, 17358000000.00 in common stock, $723.74 billion in retained earnings and $0 in goodwill. Its cash balance stood at $60.43 billion and cash and short-term investments were $128.79 billion. The company’s total short-term debt was $2,433,000,000 while long-term debt stood at $0.

Ono Pharmaceutical Co. Ltd’s total current assets stands at $326.15 billion while long-term investments were $0 and short-term investments were $68.36 billion. Its net receivables were $123.52 billion compared to accounts payable of $51.90 billion and inventory worth $50.39 billion.

In 2024, Ono Pharmaceutical Co. Ltd's operating cash flow was $0 while its capital expenditure stood at $7.74 billion.

Comparatively, Ono Pharmaceutical Co. Ltd paid $0.30 in dividends in 2024.

Other key metrics

Current Trading Price

$19.83

52-Week High

$25.36

52-Week Low

$17.78

Analyst Target Price

$

Ono Pharmaceutical Co. Ltd stock is currently trading at $19.83 per share. It touched a 52-week high of $25.36 and a 52-week low of $25.36. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $19.92 and 200-day moving average was $23.45 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 1598.4% of the company’s stock are held by insiders while 4605.9% are held by institutions.